Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: June 2026 (Specifically June 11, 2026)
Context: The filing reports a material corporate event regarding intellectual property rights in South Korea.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
- Intellectual Property: NeuroSense Therapeutics Ltd. was granted a South Korean patent covering its PrimeC composition for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference the first three paragraphs of a press release dated June 11, 2026, detailing the patent grant.
Outlook/Guidance: The filing text does not provide a clear value for future financial guidance or operational outlook beyond the patent milestone.
Risks/Contingencies: No specific risks or contingencies are detailed in the text of this Form 6-K.
Investor Verification Checklist
- Verify the scope and validity of the South Korean patent for the PrimeC composition.
- Review the full text of the press release (Exhibit 99.1) for details on the patent's impact on the ALS treatment pipeline.
- Confirm the status of PrimeC clinical trials in other jurisdictions to assess global commercial potential.